Revenue
2020
2021
2022
2023
2024
2025
Roivant Sciences Ltd. (ROIV)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M | $23.8M |
| Research & development | $681.8M | $550.4M | $439.9M | $454.1M | $483.0M | $236.6M |
| Operating expenses | $1.29B | $1.14B | $884.1M | $938.3M | $1.41B | $1.09B |
| Operating income | −$515.1M | −$1.00B | $4.50B | −$906.8M | −$1.35B | −$1.07B |
| EBITDAderived | −$511.7M | −$989.2M | $4.52B | −$887.9M | −$1.35B | — |
| Net income | −$299.8M | −$172.0M | $4.35B | −$1.01B | −$845.3M | −$809.2M |
| Basic EPSper diluted share | -$0.43 | -$0.24 | $5.55 | -$1.42 | -$1.26 | -$1.28 |
| Diluted EPSper diluted share | -$0.54 | -$0.24 | $5.23 | -$1.42 | -$1.26 | -$1.28 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 30, 2026Form 4 | MANCHESTER KEITH SDirector | SellCommon Shares | 200.0K | $35.45 | $7.09M | 1.75M |
| Jun 30, 2026Form 4 | MANCHESTER KEITH SDirector | SellCommon Shares · indirect | 12.4K | $35.28 | $436.8K | 13.69M |
| Jun 30, 2026Form 4 | Gold Daniel AllenDirector | SellCommon Shares · indirect | 12.4K | $35.28 | $436.8K | 13.69M |
| Jun 30, 2026Form 4 | QVT Financial LPOther | SellCommon Shares · indirect | 12.4K | $35.28 | $436.8K | 13.69M |
| Jun 29, 2026Form 4 | MANCHESTER KEITH SDirector | SellCommon Shares · indirect | 600.0K | $34.59 | $20.75M | 13.70M |